• More research needed to realize true benefit of PARP inhibitors in breast cancer

    12 days ago - By Healio

    NEW YORK - The effectiveness of PARP inhibitors demonstrate a proof of principle that targeting DNA repair pathways can be a productive treatment strategy, but more research is necessary to extend their benefit, according to a presenter at Chemotherapy Foundation Symposium.
    “Single-agent therapy benefit so far has only been demonstrated in patients with germline BRCA mutations. We don't have data yet regarding somatic BRCA mutations in breast cancer,” Mark Robson, MD, chief of the breast medicine service at Memorial Sloan Kettering Cancer Center and professor of
    Read more ...